News | February 09, 2023
JB Pharma records revenue growth of 32% to Rs. 793 Cr in Q3 FY23
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
For discovery or for standardization, Ayurveda colleges/institutes need to collaborate closely with Phytochemists, Pharmacologists, and Toxicologists from premier institutions
Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure
The new facility will be able to handle four times as many patients as the previous facility.
Selexipag tablet is indicated in adults for the treatment of pulmonary arterial hypertension to delay disease progression and reduce the risk of hospitalization for PAH
The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
The newly built complex of RRIUM, which will be under CCRUM, the apex government organization for research in Unani Medicine
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
Subscribe To Our Newsletter & Stay Updated
